IRVING, Texas (BUSINESS WIRE), March 02, 2020 - Vizient, Inc. recently shared insights on chimeric antigen receptor T-cell (CAR-T) data and its implications for patients with cytokine release syndrome, large B-cell cancer, and pediatric and young adult patients with leukemia. Analyses were derived using Vizient’s Clinical Data Base/Resource Manager (CDB/RM™) and presented as posters at the 2020 Transplantation & Cellular Therapy Meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) held Feb. 19-23 in Orlando.
The meeting included clinicians, administrators, clinical research professionals, laboratory technicians and pharmacists and focused on issues in hematopoietic cell transplantation and cellular therapy. Vizient‘s Alyssa Hartsell Harris, presented three posters at the event:
Real-World Quality and Cost Burden of Cytokine Release Syndrome (CRS) Requiring Tocilizumab or Steroids during CAR-T Infusion Encounter. The poster covered a retrospective cohort of 1,570 CAR-T infusion encounters for patients 18 years and older undergoing CAR-T procedures for diffuse large B-cell lymphoma from October 2017 to July 2019. It described the length of stay, costs and hospital mortality rates across patients who received tocilizumab and dexamethasone or prednisolone to treat CRS, a serious adverse event after CAR-T infusion.
Quality and Cost Outcomes in Chimeric Antigen Receptor T-Cell Immunotherapy in Adult Large B-Cell Cancer Patients from the Vizient Clinical Database. The poster covered a retrospective cohort of 1,570 patients 18 years and older undergoing CAR-T procedures from October 2017 to July 2019. It described unplanned readmission rates, adverse events due to the immunotherapy as well as provided a cost analysis.
Quality and Cost Outcomes in Chimeric Antigen Receptor T-cell Immunotherapy in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia from the Vizient Clinical Database. The poster covered a retrospective cohort of 139 patients 25 years and under undergoing CAR-T procedures between October 2017 and October 2019. It described inpatient and outpatient mortality, length of stay, readmissions and provided a cost analysis.
“The collection of CAR-T data within our clinical data base continues to improve and is beginning to offer interesting insights into this new therapy,” said Gladys J. Epting, Ph.D., associate vice president, analytics, at Vizient. “It is exciting to see how the data is demonstrating the clinical response by patients as well as cost and outcomes. These insights will help shape next steps for both clinicians and payers.”
About Vizient, Inc.
Vizient, Inc. provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nation’s acute care providers, which includes 95% of the nation’s academic medical centers, and more than 20% of ambulatory providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Vizient has earned a World’s Most Ethical Company designation from the Ethisphere Institute every year since its inception. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200302005146/en/